Barclays analyst Hang Hu assumed coverage of Cytokinetics (CYTK) with an Overweight rating and $87 price target The firm says that given a “differentiated” label with flexibility of titration, it continues to view Myqorzo as a preferred drug over Camzyos in obstructive hypertrophic cardiomyopathy.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics, Olympic Medalist McLaughlin-Levrone team up for awareness for HCM
- Cytokinetics announces Myqorzo available in U.S.
- Cytokinetics price target raised to $108 from $90 at B. Riley
- 3 ‘Strong Buy’ Stocks to Buy Today, 1/14/2026, According to Top Analysts
- Cytokinetics price target raised to $90 from $71 at Morgan Stanley